Nuvation Bio Shares Surge 8% Amidst Insider Buying and FDA Approval Impact

Nuvation Bio (NUVB) shares surged 8% after CEO David Hung purchased $1.1 million worth of stock, boosting insider buying activity. Analysts predict a substantial upside potential with a one-year price target average of $7.17, representing a 276.20% potential increase from the current trading price. The favorable outlook is reflected in Nuvation Bio's "Outperform" rating with an average brokerage recommendation of 1.7.

Nuvation Bio Inc. (NYSE:NUVB) saw its stock price surge by 8% on June 19, 2025, following significant insider buying activity. The company's CEO, David Hung, purchased $1.1 million worth of shares, boosting insider buying activity [2]. This purchase comes amidst a positive outlook from analysts, who predict a substantial upside potential for the stock.

Analysts have set a one-year price target average of $7.17 for NUVB, representing a potential 276.20% increase from the current trading price of $1.91 [2]. The favorable outlook is reflected in Nuvation Bio's "Outperform" rating, with an average brokerage recommendation of 1.7 [2].

Market analysts have positioned their estimates between a high of $10.00 and a low of $5.00, with a consensus price target of $7.40, representing a 313.41% change from the last price of $1.79 [3]. This positive sentiment underscores the optimism surrounding Nuvation Bio's potential for growth and recovery.

References:
[1] https://www.marketbeat.com/instant-alerts/nuvation-bio-nysenuvb-shares-gap-up-heres-why-2025-06-20/
[2] https://www.gurufocus.com/news/2937324/insider-buying-boosts-nuvation-bio-nuvb-shares-amidst-fda-approval-impact
[3] https://www.tipranks.com/stocks/nuvb/forecast